13 completed, 2 terminated, 1 recruiting, 1 unknown. 17 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 13, Terminated 2, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow Bacterial Conjunctivitis: new trials by email Literature Review of Bacterial Conjunctivitis trials Research Report on Bacterial Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis Fusidic Acid 1%, Placebo - Bacterial Conjunctivitis | Phase 3 | Recruiting | Baxis Pharmaceuticals, Inc. | 400 | 2025-03-21 | 2026-03-17 |
| Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo SHP640, PVP-I 0.6%, Placebo - Bacterial Conjunctivitis | Phase 3 | Completed | Shire | 753 | 2017-03-29 | 2021-06-09 |
| Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis Vancomycin 1.1%, Placebo - Bacterial Conjunctivitis | Phase 3 | Completed | Kurobe LLC | 303 | 2015-05-01 | 2024-10-23 |
| Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis Besifloxacin, Vehicle - Bacterial Conjunctivitis | Phase 3 | Terminated | Bausch & Lomb Incorporated | 136 | 2013-02-01 | 2014-10-01 |
| An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Moxifloxacin ophthalmic solution, 0.5%, Ofloxacin ophthalmic solution, 0.3% - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 985 | 2012-05-01 | 2015-05-12 |
| Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis Besivance, Gatifloxacin - Bacterial Conjunctivitis | Phase 3 | Terminated | Bausch & Lomb Incorporated | 33 | 2011-05-01 | 2014-09-03 |
| Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis MAXINOM®, Maxitrol® - Bacterial Conjunctivitis, Acute | Phase 3 | Unknown | Azidus Brasil | 70 | 2011-02-01 | 2010-10-25 |
| Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Besivance, Vehicle - Bacterial Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 518 | 2010-06-01 | 2013-05-01 |
| Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Besifloxacin, Vehicle (Placebo) - Bacterial Conjunctivitis | Phase 2 / Phase 3 | Completed | Bausch & Lomb Incorporated | 474 | 2009-10-01 | 2012-03-29 |
| Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, Moxifloxacin AF Vehicle - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 1179 | 2008-10-01 | 2018-01-02 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 859 | 2008-02-01 | 2019-04-23 |
| A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Gatifloxacin 0.5% eye drops, placebo eye drops - Bacterial Conjunctivitis | Phase 3 | Completed | Allergan | 578 | 2007-08-01 | 2011-11-30 |
| AL-15469A for the Treatment of Bacterial Conjunctivitis Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 695 | 2006-05-01 | 2016-11-18 |
| AL-15469A for the Treatment of Bacterial Conjunctivitis quinolone - Bacterial Conjunctivitis | Phase 3 | Completed | Alcon Research | 600 | 2005-11-01 | 2009-09-29 |
| Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis 0.5% levofloxacin eye drops - Bacterial Conjunctivitis | Phase 2 / Phase 3 | Completed | Laser Microsurgery Centre, Poland | 119 | 2004-09-01 | 2007-11-29 |
| Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004) AzaSite, Tobramycin - Bacterial Conjunctivitis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 743 | 2004-07-01 | 2013-12-16 |
| Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) AzaSite, Vehicle - Bacterial Conjunctivitis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 685 | 2004-07-01 | 2013-11-21 |
Conjunctivitis, Bacterial (17) · Conjunctivitis (4) · Eye Infections (3) · Eye Infections, Bacterial (2) · Bacterial Infections (1) · Conjunctival Diseases (1) · Eye Diseases (1) · Infections (1)
Bacterial Infections and Mycoses (17) · Bacterial Infections (16) · Conjunctival Diseases (16) · Eye Diseases (16) · Infections (16) · Eye Infections, Bacterial (15) · Eye Infections (14) · Conjunctivitis (13)
besifloxacin (4) · Gatifloxacin (3) · Azithromycin (2) · Moxifloxacin (2) · Ophthalmic Solutions (2) · Alkalies (1) · Maxitrol (1) · Quinolones (1) · Tobramycin (1)
Alcon Research (4) · Bausch & Lomb Incorporated (4) · Allergan (2) · Merck Sharp & Dohme LLC (2) · Azidus Brasil (1) · Baxis Pharmaceuticals, Inc. (1) · Kurobe LLC (1) · Laser Microsurgery Centre, Poland (1) · Shire (1)
United States (13) · Poland (2) · Australia (1) · Austria (1) · Brazil (1) · Canada (1) · China (1) · Estonia (1) · France (1) · Hungary (1) · India (1) · Israel (1) · Italy (1) · Puerto Rico (1) · South Africa (1)
Johnson Varughese (2) · Catherine Allaire, MD (1) · Helen Yu, Lead CSM (1) · Jerzy Szaflik, MD,Ph.D. (1) · Michael R Paterno, OD (1) · Stella Robertson, Ph.D. (1)
PMID 21681652, PMID 17652708, PMID 18374301, PMID 21397770, PMID 22420526, PMID 22644963, PMID 25244402
2016 (1)